These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 38773786)

  • 1. Editorial: Infliximab induction therapy in pediatric Crohn's disease-A cost-effective strategy?
    Chanchlani N; Russell RK
    Aliment Pharmacol Ther; 2024 Jul; 60(1):93-94. PubMed ID: 38773786
    [No Abstract]   [Full Text] [Related]  

  • 2. Editorial: Infliximab induction therapy in paediatric Crohn's disease - A cost-effective strategy? Authors' reply.
    Vuijk SA; de Ridder L
    Aliment Pharmacol Ther; 2024 Jul; 60(1):95-96. PubMed ID: 38773791
    [No Abstract]   [Full Text] [Related]  

  • 3. Incorrect cost of infliximab in fistulizing Crohn's disease.
    Lichtenstein GR
    Gastroenterology; 2004 Aug; 127(2):691-2; author reply 692-3. PubMed ID: 15300614
    [No Abstract]   [Full Text] [Related]  

  • 4. The real cost of pediatric Crohn's disease: the role of infliximab in the treatment of pediatric IBD.
    Kay M; Wyllie R
    Am J Gastroenterol; 2003 Apr; 98(4):717-20. PubMed ID: 12738445
    [No Abstract]   [Full Text] [Related]  

  • 5. The cost-effectiveness of infliximab in Crohn's disease.
    Smart C; Selinger CP
    Expert Rev Pharmacoecon Outcomes Res; 2014 Oct; 14(5):589-98. PubMed ID: 25138162
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Costs of care for Crohn's disease following the introduction of infliximab: a single-centre UK experience.
    Sprakes MB; Ford AC; Suares NC; Warren L; Greer D; Donnellan CF; Jennings JS; Everett SM; Hamlin PJ
    Aliment Pharmacol Ther; 2010 Dec; 32(11-12):1357-63. PubMed ID: 21050238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Infliximab use in patients with Crohn's disease: quality of life, costs and resource use.
    Koelewijn C; Schrijvers A; Oldenburg B
    Neth J Med; 2006; 64(7):212-8. PubMed ID: 16929082
    [No Abstract]   [Full Text] [Related]  

  • 8. Cost-effectiveness analysis of top-down versus step-up strategies in patients with newly diagnosed active luminal Crohn's disease.
    Marchetti M; Liberato NL; Di Sabatino A; Corazza GR
    Eur J Health Econ; 2013 Dec; 14(6):853-61. PubMed ID: 22975794
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Costs of adalimumab versus infliximab as first-line biological therapy for luminal Crohn's disease.
    Choi GK; Collins SD; Greer DP; Warren L; Dowson G; Clark T; Hamlin PJ; Ford AC
    J Crohns Colitis; 2014 May; 8(5):375-83. PubMed ID: 24129316
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomised clinical trial: First-line infliximab biosimilar is cost-effective compared to conventional treatment in paediatric Crohn's disease.
    Vuijk SA; Jongsma MME; Hoeven BM; Cozijnsen MA; van Pieterson M; de Meij TGJ; Norbruis OF; Groeneweg M; Wolters VM; van Wering H; Hummel T; Stapelbroek J; van der Feen C; van Rheenen PF; van Wijk MP; Teklenburg S; Rizopoulos D; Poley MJ; Escher JC; de Ridder L
    Aliment Pharmacol Ther; 2024 Jun; 59(12):1510-1520. PubMed ID: 38644588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-Effectiveness of Reimbursing Infliximab for Moderate to Severe Crohn's Disease in China.
    Chen H; Shi J; Pan Y; Zhang Z; Fang H; Chen Y; Chen W; Cao Q
    Adv Ther; 2020 Jan; 37(1):431-449. PubMed ID: 31797196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytokine-target therapies cost effective in Crohn's disease?
    McClellan K
    Drugs R D; 1999 Mar; 1(3):273-4. PubMed ID: 10566045
    [No Abstract]   [Full Text] [Related]  

  • 13. Funding the new biologics--what can we learn from infliximab? The CCOHTA report: a gastroenterologist's viewpoint.
    Hilsden R
    Can J Gastroenterol; 2002 Dec; 16(12):865-8. PubMed ID: 12522477
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How costly is non-adherence to infliximab in patients with Crohn's disease?
    Selinger CP
    J Med Econ; 2014 Dec; 17(12):881-2. PubMed ID: 25243913
    [No Abstract]   [Full Text] [Related]  

  • 15. Funding the new biologics--a health economic critique of the CCOHTA report: infliximab for the treatment of Crohn's disease.
    Mitton CR;
    Can J Gastroenterol; 2002 Dec; 16(12):873-6. PubMed ID: 12522479
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Infliximab for the treatment of Crohn's disease: efficacy, safety and pharmacoeconomics.
    Feagan BG; Enns R; Fedorak RN; Panaccione R; Paré P; Steinhart AH; Wild G
    Can J Clin Pharmacol; 2001; 8(4):188-98. PubMed ID: 11743591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-utility of biological treatment sequences for luminal Crohn's disease in Europe.
    Rencz F; Gulácsi L; Péntek M; Gecse KB; Dignass A; Halfvarson J; Gomollón F; Baji P; Peyrin-Biroulet L; Lakatos PL; Brodszky V
    Expert Rev Pharmacoecon Outcomes Res; 2017 Dec; 17(6):597-606. PubMed ID: 28434387
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A UK retrospective observational study of clinical outcomes and healthcare resource utilisation of infliximab treatment in Crohn's disease.
    Lindsay JO; Chipperfield R; Giles A; Wheeler C; Orchard T;
    Aliment Pharmacol Ther; 2013 Jul; 38(1):52-61. PubMed ID: 23701393
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Number needed to treat and cost per remitter for biologic treatments of Crohn's disease in Japan.
    Ueno F; Doi M; Kawai Y; Ukawa N; Cammarota J; Betts KA
    J Med Econ; 2020 Jan; 23(1):80-85. PubMed ID: 31294641
    [No Abstract]   [Full Text] [Related]  

  • 20. Value Assessment and Quantitative Benefit-Risk Modelling of Biosimilar Infliximab for Crohn's Disease.
    Catt H; Bodger K; Kirkham JJ; Hughes DA
    Pharmacoeconomics; 2019 Dec; 37(12):1509-1523. PubMed ID: 31372948
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.